Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGNK 001

Next Previous
X
Search
Drug Profile

IGNK 001

Alternative Names: IGNK 001 - Gengleucel; IGNK-001

Latest Information Update: 20 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ingenium Therapeutics
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 30 Apr 2024 Phase-II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in South Korea (Parenteral) before April 2024
  • 30 Apr 2024 IGNK 001 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 30 Apr 2024 Korean Ministry of Food and Drug Safety approves regulatory application for IGNK 001 for phase II clinical trials in Acute myeloid leukemia before April 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top